

Prevalence and risk factors of poor sleep quality in continuous ambulatory peritoneal dialysis patients in Nanchang, Southeast China

Caixia Yan^a, Chuanfei Zeng^b, Yujiao Ma^a, Xiaojiang Zhan^b and Yan Min^c

^aDepartment of Nephrology, The First Affiliated Hospital of Nanchang University, Nanchang, China; ^bJiangxi Medical College, Nanchang University, Nanchang, China; ^cDepartment of Nursing, First Affiliated Hospital of Nanchang University, Nanchang, China

ABSTRACT

This study aimed to explore the prevalence and risk factors of poor sleep quality in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) at the peritoneal dialysis center of the First Affiliated Hospital of Nanchang University. This cross-sectional study was conducted from March 2019 to December 2019. The Pittsburgh Sleep Quality Index (PSQI) was used to evaluate the sleep quality of patients undergoing CAPD. A PSQI score of ≥ 5 was defined as poor sleep quality, whereas a PSQI of < 5 was defined as good sleep quality. Logistic regression analysis was used to analyze risk factors for poor sleep quality. In total, 456 patients undergoing CAPD were investigated. The average PSQI score was 5.0 ± 2.9 . Among the participants, 46.3% had poor sleep quality, and 45.6% were female patients. The average age was 49.4 ± 13.3 years. Compared with good sleepers, poor sleepers included a higher proportion of females and calcium-phosphorus ($\text{Ca} \times \text{P}$) product, longer dialysis durations, lower total endogenous creatinine clearance rates, less residual renal function, and lower albumin levels. Multivariate logistic regression analysis showed that a long dialysis duration, low albumin level, and high $\text{Ca} \times \text{P}$ product were independent risk factors for poor sleep quality in patients undergoing CAPD. Odds ratios (95% confidence interval) for these risk factors were 1.01 (1.00–1.02), 0.95 (0.91–1.00), and 1.02 (1.00–1.03), respectively. Interventions aimed at improving albumin and $\text{Ca} \times \text{P}$ product levels may improve quality of life for CAPD patients.

ARTICLE HISTORY

Received 9 March 2022
Revised 23 June 2022
Accepted 29 June 2022

KEYWORDS

Continuous ambulatory peritoneal dialysis; sleep quality; Pittsburgh Sleep Quality Index; risk factors



Introduction

Sleep disorders are common complications of end-stage renal disease (ESRD), and they are the main factors leading to death and decline in quality of life in patients with ESRD [1,2]. It is estimated that about 45%–85% of patients undergoing hemodialysis and 43%–80% of patients undergoing continuous ambulatory peritoneal dialysis (CAPD) have various sleep disorders [1,3–6]. Sleep disorders include insomnia, sleep apnea syndrome, hypopnea syndrome, central sleep apnea, central drowsiness, diurnal sleep awakening disorder, unconscious sleep, and restless leg syndrome [1,7–9]. Most dialysis patients have at least one sleep disorder [7]. The main manifestations are difficulty falling asleep, sleep maintenance disorder, early awakening, decreased sleep quality, and decreased total sleep time.

The causes of poor sleep quality in patients undergoing CAPD are not fully understood and may be

multifactorial. Previous studies have shown that male sex [10], old age [11], depression [12], anemia [13], uremic pruritus [14], low serum vitamin D [15], and duration of dialysis [16] all contributed to sleep disturbances in dialysis patients. In addition, Li *et al.* [4] found that high calcium-phosphorus ($\text{Ca} \times \text{P}$) product, low subjective global assessment scores, and high malnutrition-inflammation scores predicted poor sleep quality in patients with CAPD. However, due to discrepancies in race, region, center, and socioeconomic status, there may be differences in the management of patients undergoing peritoneal dialysis (PD), which eventually lead to inconsistencies in the prevalence and risk factors of poor sleep quality. Furthermore, related research on poor sleep quality is limited to the underdeveloped areas of China.

Since poor sleep quality are the main complaints and strong predictors of mortality of patients undergoing PD, it is necessary to determine coexisting clinical

CONTACT A.P. Yan Min  minyan329@163.com  Department of Nursing, First Affiliated Hospital of Nanchang University, 17# Yongwai Street, Nanchang, 330006, China

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Enrollment flow chart of this study. PD: Peritoneal dialysis; PSQI: Pittsburgh Sleep Quality Index.

and modifiable biochemical disorders. Therefore, this study aimed to investigate the prevalence and potential risk factors of poor sleep quality in patients undergoing PD in Southeast China.

Materials and methods

Study population

To investigate the prevalence and risk factors of poor sleep quality at the First Affiliated Hospital of Nanchang University, a survey was conducted from March 2019 to December 2019. A total of 456 patients undergoing CAPD were enrolled in this study. The inclusion criteria included age of ≥ 18 years and CAPD of ≥ 3 months. Exclusion criteria included mental illness, malignant history, cardiovascular history, and trauma or surgery in the month prior to the study. The study was approved by the Human Ethics Committee of Nanchang University (Application ID: [2019] 032),

and written informed consent was obtained from each participant.

Assessment of sleep quality

The Pittsburgh Sleep Quality Index (PSQI) [17] is a common tool for assessing sleep problems associated with anxiety, stress, depression, and schizophrenia. It is divided into seven parts: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, the use of sleep medications, and daytime dysfunction caused by sleep disorders. The score of each part is 0–3, and the highest total score is 21. A score of < 5 indicates good sleep quality, and > 5 indicates poor sleep quality. A higher score indicates worse sleep quality.

Questionnaires

Questionnaires were administered at the outpatient visits of patients who were regularly followed up.

Table 1. Comparison of demographic and laboratory data between good sleepers and poor sleepers.

Variables	All patients N = 456	Good sleepers (PSQI < 5) N = 245	Poor sleepers (PSQI ≥ 5) N = 211	p values
PSQI	5.0 ± 2.9	3.0 ± 0.9	7.4 ± 2.6	
Men, n (%)	248 (54.4)	145 (59.2)	103 (48.8)	0.027
Age (year)	49.4 ± 13.3	48.7 ± 13.6	50.1 ± 12.9	0.298
Duration of CAPD (months)	27.5 (13.3 – 55.3)	24.9 (11.9 – 42.1)	33.2 (14.0 – 70.5)	<0.001
CCI score	2.58 ± 0.91	2.58 ± 0.90	2.57 ± 0.93	0.861
BMI	21.6 ± 3.6	21.5 ± 3.7	21.8 ± 3.5	0.411
Diabetes, n (%)	82 (18.0)	41 (16.7)	41 (19.4)	0.455
Hypertension, n (%)	369 (80.9)	198 (80.8)	171 (81.0)	0.951
Total Kt/V	1.73 (1.34 – 2.25)	1.79 (1.39 – 2.24)	1.69 (1.30 – 2.26)	0.530
Total Ccr	55.09 (45.93 – 72.02)	59.89 (47.49 – 75.35)	51.36 (44.06 – 63.61)	<0.001
eGFR (mL/min/1.73 m ²)	1.05 (0.00 – 3.12)	1.64 (0.01 – 3.77)	0.45 (0.00 – 2.37)	<0.001
Hemoglobin (g/L)	106 ± 22	108 ± 21	105 ± 23	0.153
Creatinine (μmol/L)	889 (657 – 1138)	876 (644 – 1151)	907 (676 – 1124)	0.718
Uric acid (μmol/L)	396 ± 88	402 ± 94	389 ± 81	0.138
Albumin (g/L)	38.6 (35.2 – 41.8)	39.4 (39.4 – 42.2)	37.8 (34.6 – 40.9)	0.005
Total cholesterol (mmol/L)	4.73 ± 1.04	4.76 ± 1.11	4.69 ± 0.96	0.456
Triglyceride (mmol/L)	1.54 (1.13 – 2.26)	1.57 (1.15 – 2.24)	1.50 (1.12 – 2.33)	0.472
Ca × P product (mg ² /dL ²)	42.5 (34.3 – 53.1)	41.4 (32.7 – 51.7)	44.4 (36.2 – 55.1)	0.014
iPTH (pg/mL)	487 (269 – 881)	504 (276 – 877)	469 (242 – 931)	0.748
C-reactive protein (mg/L)	0.70 (0.30 – 2.00)	0.63 (0.30 – 1.72)	0.79 (0.35 – 2.37)	0.160

BMI: Body mass index; Ca × P product: calcium-phosphorus product; CAPD: Continuous ambulatory peritoneal dialysis; CCI: Charlson comorbidity index; Ccr: Endogenous creatinine clearance rate; eGFR: Estimated glomerular filtration rate; iPTH: Intact parathyroid hormone; PSQI: Pittsburgh sleep quality index.

Otherwise, nurses telephoned the patients to gather information. At the outpatient visit, the questionnaires were issued, explained, and recycled by PD nurses. The questionnaires were filled out by the patients or nurses, if patients were illiterate, when they were available to answer questions without interfering with the answers of the participants. Finally, data were independently extracted by two PD doctors.

Basic information collection

Demographic, clinical and laboratory information were extracted from the patients' medical records, retrospectively. The data included sex, age, duration of CAPD, Charlson Comorbidity Index (CCI) score, body mass index (BMI), diabetes, hypertension, total Kt/V, total endogenous creatinine clearance rate (Ccr), estimated glomerular filtration rate (eGFR), hemoglobin, creatinine, uric acid, albumin, total cholesterol, triglyceride, Ca × P product, intact parathyroid hormone (iPTH), and C-reactive protein. Baseline residual renal function (RRF) was assessed by eGFR using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation [18].

Statistical analysis

SPSS (version 22.0; IBM Corp., Armonk, NY, USA) was used for the statistical analysis. A *p*-value of <0.05 was regarded as statistically significant. Categorical variables were expressed as frequencies and percentages, and continuous variables were expressed as means and

standard deviations or medians and interquartile ranges. Student's *t* test, Mann-Whitney U test, and chi-squared test were used for comparisons. Univariate and multivariate logistic analyses were also performed. Covariates considered to be clinically significant or with a *p*-value of <0.05 in the univariate logistic regression were chosen for multivariate logistic regression.

Results

Baseline characteristics of participants undergoing CAPD

Among the 456 participants in the study, the average PSQI score was 5.0 ± 2.9. While 245 patients were good sleepers (PSQI < 5), 211 were poor sleepers (PSQI ≥ 5) (Figure 1). The prevalence of poor sleep quality was 46.3%, the mean age was 49.4 ± 13.3 years, and 45.6% were female. The baseline eGFR was 1.05 mL/min/1.73 m² (range, 0.00–3.12). The baseline characteristics of the participants, stratified by PSQI score, are shown in Table 1. The average PSQI scores of poor sleepers and good sleepers were 7.4 ± 2.6 and 3.0 ± 0.9, respectively. The duration of CAPD was significantly longer in poor sleepers (33.2 vs. 24.9 months; *p* < 0.001). The mean values of total Ccr, eGFR, albumin, and the proportion of men were significantly lower in poor sleepers. The mean Ca × P product of poor sleepers was higher than that of good sleepers at baseline (*p* = 0.014).

Table 2. Risk factors related to poor sleep quality in patients undergoing CAPD: univariate logistic and multivariate logistic regression analysis.

Variables	Univariate logistic regression		Multivariate logistic regression	
	OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value
Male	0.67 (0.45 – 0.95)	0.027	0.78 (0.52 – 1.16)	0.221
Age (year)	1.01 (0.99 – 1.02)	0.289	1.00 (0.99 – 1.02)	0.682
Duration of CAPD (month)	1.02 (1.01 – 1.02)	<0.001	1.01 (1.00 – 1.02)	0.003
CCI score	0.98 (0.80 – 1.20)	0.861		
BMI	1.02 (0.97 – 1.08)	0.411		
Total Kt/V	0.98 (0.97 – 1.01)	0.786		
Total Ccr	0.99 (0.98 – 1.00)	0.002	0.91 (0.79 – 1.06)	0.228
eGFR (mL/min/1.73 m ²)	0.89 (0.82 – 0.96)	0.002	2.43 (0.56 – 10.59)	0.238
Hemoglobin (g/L)	0.99 (0.99 – 1.00)	0.153		
Albumin (g/L)	0.94 (0.91 – 0.98)	0.004	0.95 (0.91 – 1.00)	0.034
Total cholesterol (mmol/L)	0.93 (0.78 – 1.12)	0.455		
Triglyceride (mmol/L)	0.93 (0.78 – 1.12)	0.446		
Ca × P product (mg ² /dL ²)	1.02 (1.00 – 1.03)	0.010	1.02 (1.00 – 1.03)	0.046
C-reactive protein (mg/L)	1.04 (0.97 – 1.13)	0.269		

BMI: Body mass index; Ca × P product: calcium-phosphorus product; CAPD: Continuous ambulatory peritoneal dialysis; CCI: Charlson comorbidity index; Ccr: Endogenous creatinine clearance rate; eGFR: Estimated glomerular filtration rate.

Risk factors for poor sleep quality in patients undergoing CAPD

Table 2 shows the risk factors for poor sleep quality in patients undergoing CAPD. Several factors were univariately associated with poor sleep quality, including female sex, duration of CAPD, total Ccr, eGFR, albumin, and Ca × P product. In the multivariable analysis, the duration of CAPD (odds ratio [OR] = 1.01, 95% confidence interval [CI] = 1.00–1.02, *p* = 0.003), albumin (OR = 0.95, 95% CI = 0.91–1.00, *p* = 0.034), and Ca × P product (OR = 1.02, 95% CI = 1.00–1.03, *p* = 0.046) were independently associated with poor sleep quality.

Discussion

This study shows that the prevalence of poor sleep quality in our center is 46.3%, similar to previous studies [5,6]. In addition, patients with poor sleep quality are usually characterized by female sex, long CAPD duration, low total Ccr, low eGFR, low albumin level, and high Ca × P product. Combined with the results of univariate and multivariate analyses, this study found that a long CAPD duration, low albumin level, and high Ca × P product were independent risk factors for poor sleep quality.

Many factors presumably contribute to the high prevalence of sleep disturbances in patients undergoing PD, including demographic, clinical, psychological, metabolic, and nutritional abnormalities. In the present study, patients with poor sleep quality tended to be female, which is inconsistent with a previous study [10]. A plausible explanation is that during times of hormonal changes, women are at an increased risk of sleep disturbances [19]. Another study showed that women were more prone to anxiety and depression

[20]. Moreover, RRF was poorer in poor sleepers. In general, a decline in RRF is accompanied by an increased risk of metabolic and cardiovascular complications, mineral and bone disorders, and poor nutritional status [21–23]. In addition to the aforementioned confounding factors that may affect sleep quality, deterioration of RRF could lead to uremia-induced neuropathy or myopathy, altered chemosensitivity, and hypervolemia, resulting in sleep disorders [24].

Our study demonstrated a significantly higher risk of poor sleep quality in patients with a longer dialysis duration and a higher Ca × P product. These findings are consistent with those of the previous studies. Generally, long dialysis duration is often accompanied by inadequate dialysis [25], malnutrition [26], depression [27], or abnormal calcium and phosphorus metabolism [11], which are well-known risk factors for sleep disturbances. A high Ca × P product may be related to secondary hyperparathyroidism, uremic pruritus, bone pain, coronary artery calcification, and increased cardiovascular diseases [11,28], which may further affect the sleep quality of patients undergoing CAPD.

Nutritional status is a risk factor for poor sleep quality in patients with CAPD. Serum albumin level, a well-known nutritional indicator, was significantly lower in poor sleepers than in good sleepers in the present study. In the multivariate logistic regression analysis, albumin level was negatively correlated with poor sleep quality. In a study conducted by Li *et al.* [4], the PSQI score was found to be negatively correlated with serum albumin and subjective global assessment score, but positively correlated with malnutrition–inflammation score. Both were measures of protein-energy wasting in CAPD patients. Similar findings have been reported previously [6,29,30]. The possible mechanisms by which nutritional status affects sleep quality are as follows:

first, nutrition can directly or indirectly contribute to poor sleep quality by affecting the hormones and inflammation status [31]; second, serum albumin level was negatively related to the intensity of uremic pruritus, which affects the quality of sleep in patients undergoing CAPD [14]; and third, low serum albumin level is an important determinant of overhydration in CAPD patients [32], which contributes to obstructive sleep apnea, not only by its effects on upper airway collapsibility but also by potentially affecting ventilatory instability [24].

Effective intervention and treatment of risk factors for poor sleep quality may improve the sleep quality of patients undergoing CAPD. This study confirms that a long dialysis duration, low albumin level, and high $\text{Ca} \times \text{P}$ product are the main factors affecting sleep quality in patients undergoing CAPD. Therefore, these factors can become new predictors of poor sleep quality and have important clinical significance. However, this study has some limitations. First, the PSQI questionnaire is a commonly used tool to evaluate only sleep quality, and there may be some errors due to recall bias and subjective judgment. Second, the present study was a cross-sectional study, the sample size was insufficient, and other potential risk factors that may affect sleep quality were not evaluated, such as monocytes, neutrophils, oxidative stress, and other inflammatory cells or factors related to poor sleep quality. Third, this study did not fully assess the nutritional status of patients or the presence of depression and other common factors affecting sleep quality.

Conclusions

In conclusion, this study showed that long dialysis duration, low albumin level, and high $\text{Ca} \times \text{P}$ product are the main predictors of poor sleep quality. Our findings may be helpful for the treatment of poor sleep quality in patients undergoing CAPD.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions

CXY designed the study. YJM and XJZ analyzed and interpreted the data regarding the PD patients. CXY and CFZ were the major contributors to the writing of the manuscript. YM revised the manuscript accordingly. All authors have read and approved the final manuscript.

Data availability statement

Raw data were generated at the First Affiliated Hospital of Nanchang University, China. The derived data supporting the findings of this study are available from the corresponding author, YM, upon request.

Funding

This study was supported by the Natural Science Foundation of Jiangxi Province, China [20212BAB216020], the Scientific Research Fund of Jiangxi Education Department [GJJ170067], and the Science and Technology Program of Jiangxi Health Commission [202130324].

References

- [1] So JY, Warburton KM, Rosen IM. A guide to management of sleepiness in ESKD. *Am J Kidney Dis.* 2020; 75(5):782–792.
- [2] De Silva I, Evangelidis N, Hanson CS, SONG-HD, SONG-PD initiative, et al. Patient and caregiver perspectives on sleep in dialysis. *J Sleep Res.* 2021;30(4):e13221.
- [3] Elder SJ, Pisoni RL, Akizawa T, et al. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). *Nephrol Dialysis Transplant.* 2007;23(3):998–1004.
- [4] Li J, Guo Q, Ye X, et al. Prevalence and risk factors of sleep disturbance in continuous ambulatory peritoneal dialysis patients in Guangzhou, Southern China. *Int Urol Nephrol.* 2012;44(3):929–936.
- [5] Guney I, Biyik M, Yeksan M, et al. Sleep quality and depression in peritoneal dialysis patients. *Renal Failure.* 2008;30(10):1017–1022.
- [6] Li H, Li X, Feng S, et al. Sleep disorders and its related risk factors in patients undergoing chronic peritoneal dialysis. *Chin Med J (Engl).* 2014;127(7):1289–1293.
- [7] Zhao Y, Zhang Y, Yang Z, et al. Sleep disorders and cognitive impairment in peritoneal dialysis: a multi-center prospective cohort study. *Kidney Blood Press Res.* 2019;44(5):1115–1127.
- [8] Stergiannis P, Govari M, Jahaj E, et al. Sleep disorders and restless legs syndrome in hemodialysis patients in Greece: a cross-sectional study. *Adv Exp Med Biol.* 2020;1195:155–162.
- [9] Scherer JS, Combs SA, Brennan F. Sleep disorders, restless legs syndrome, and uremic pruritus: Diagnosis and treatment of common symptoms in dialysis patients. *Am J Kidney Dis.* 2017;69(1):117–128.
- [10] Lee YC, Hung SY, Wang HK, et al. Male patients on peritoneal dialysis have a higher risk of sleep apnea. *J Clin Sleep Med.* 2019;15(7):937–945.
- [11] Wang Y, Zhu J, Cao J, et al. Remote diagnosis system of uremia complicated with sleep disorder and effectiveness of nursing intervention. *Contrast Media Mol Imaging.* 2021;2021:1–6.
- [12] Tu CY, Chou YH, Lin YH, et al. Sleep and emotional disturbance in patients with non-dialysis chronic kidney disease. *J Formos Med Assoc.* 2019;118(6):986–994.

- [13] Zhang H, Yang Y, Huang J, et al. Correlates of objective sleep quality in older peritoneal dialysis patients. *Ren Fail.* 2021;43(1):180–187.
- [14] Min JW, Kim SH, Kim YO, et al. Comparison of uremic pruritus between patients undergoing hemodialysis and peritoneal dialysis. *Kidney Res Clin Pract.* 2016;35(2):107–113.
- [15] Han B, Zhu FX, Shi C, et al. Association between serum vitamin D levels and sleep disturbance in hemodialysis patients. *Nutrients.* 2017;9(2):139.
- [16] Pai MF, Hsu SP, Yang SY, et al. Sleep disturbance in chronic hemodialysis patients: the impact of depression and anemia. *Ren Fail.* 2007;29(6):673–677.
- [17] Mollayeva T, Thurairajah P, Burton K, et al. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis. *Sleep Med Rev.* 2016;25:52–73.
- [18] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. *Lancet* 2012;379(9818):815–822.
- [19] Pengo MF, Won CH, Bourjeily G. Sleep in women across the life span. *Chest* 2018;154(1):196–206.
- [20] Chueh KH, Chen KR, Lin YH. Psychological distress and sleep disturbance among female nurses: anxiety or depression? *J Transcult Nurs.* 2021;32(1):14–20.
- [21] Wu T, Qi Y, Ma S, et al. Efficacy of roxadustat on anemia and residual renal function in patients new to peritoneal dialysis. *Ren Fail.* 2022;44(1):529–540.
- [22] Wang AY, Brimble KS, Brunier G, et al. ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part I - assessment and management of various cardiovascular risk factors. *Perit Dial Int.* 2015;35(4):379–387.
- [23] Sikorska D, Pawlaczyk K, Olewicz-Gawlik A, et al. The importance of residual renal function in peritoneal dialysis. *Int Urol Nephrol.* 2016;48(12):2101–2108.
- [24] Lin CH, Lurie RC, Lyons OD. Sleep apnea and chronic kidney disease: a state-of-the-Art review. *Chest* 2020;157(3):673–685.
- [25] Li PK, Chow KM, Van de Luitgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. *Nat Rev Nephrol.* 2017;13(2):90–103.
- [26] Orozco-Gonzalez CN, Cortes-Sanabria L, Cueto-Manzano AM, et al. Prevalence of pica in patients on dialysis and its association with nutritional status. *J Ren Nutr.* 2019;29(2):143–148.
- [27] Lin J, Guo Q, Ye X, et al. The effect of social support and coping style on depression in patients with continuous ambulatory peritoneal dialysis in Southern China. *Int Urol Nephrol.* 2013;45(2):527–535.
- [28] Rivara MB, Ravel V, Kalantar-Zadeh K, et al. Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis. *JASN.* 2015;26(7):1671–1681.
- [29] Erdogan A, Dervisoglu E, Kutlu A. Sleep quality and its correlates in patients on continuous ambulatory peritoneal dialysis. *Scand J Urol Nephrol.* 2012;46(6):441–447.
- [30] Ezzat H, Mohab A. Prevalence of sleep disorders among ESRD patients. *Ren Fail.* 2015;37(6):1013–1019.
- [31] Zhao M, Tuo H, Wang S, et al. The effects of dietary nutrition on sleep and sleep disorders. *Mediators Inflamm.* 2020;2020:3142874.
- [32] Fornazari D, Antoni M, Knap B. Volume status and arterial stiffness evaluation in peritoneal dialysis patients. *Clin Nephrol.* 2021;96(Suppl 1):74–79.